IntroductionRadium-223 (223Ra) has been shown to have an overall survival benefit in metastatic castration-resistant prostate cancer (mCRPC) involving bone. Despite its increased clinical usage, relatively little is known regarding the mechanism of action of 223Ra at the cellular level.MethodsWe evaluated the effects of 223Ra irradiation in a panel of cell lines and then compared them with standard X-ray and external alpha-particle irradiation, with a particular focus on cell survival and DNA damage repair kinetics.Results223Ra exposures had very high, cell-type-dependent RBE50% ranging from 7 to 15. This was significantly greater than external alpha irradiations (RBE50% from 1.4 to 2.1). These differences were shown to be partially related...
Important consideration in development of effective radiotherapy is the nature of the radiation emit...
Bone-metastatic, castration-resistant prostate cancer (bmCRPC) represents a lethal stage of the most...
Painful bone metastases are common in prostate cancer, with current treatments including non-steroid...
Background Bone-targeting radiotherapy with Radium-223 (Rad-223), a radioisotope emitting genotoxic ...
The overarching goal of this thesis is to establish a well-characterized platform to investigate the...
The bone-seeking radiopharmaceutical Xofigo (Radium-223 dichloride) has demonstrated both extended s...
BACKGROUND: Radium-223 dichloride (radium-223), an alpha emitter, selectively targets bone metastas...
Michael R Harrison, Terence Z Wong, Andrew J Armstrong, Daniel J GeorgeDuke Cancer Institute, Durham...
The use of α-particle radionuclide emitters in the treatment of bone metastasis has been an active a...
BackgroundRadium-223 is a targeted alpha-particle therapy that improves survival in men with metasta...
Various single or multi-modality therapeutic options are available to treat pain of bone metastasis ...
IMPORTANCE Targeted alpha therapy attempts to deliver systemic radiation selectively to cancer cells...
Importance Targeted alpha therapy attempts to deliver systemic radiation selectively to cancer cells...
Radium-223 dichloride (223Ra) is the first, recently approved, α-particle-emitting radiopharmaceutic...
Review[Abstract] Radionuclides have been widely used for cancer treatment. Recently, new research ab...
Important consideration in development of effective radiotherapy is the nature of the radiation emit...
Bone-metastatic, castration-resistant prostate cancer (bmCRPC) represents a lethal stage of the most...
Painful bone metastases are common in prostate cancer, with current treatments including non-steroid...
Background Bone-targeting radiotherapy with Radium-223 (Rad-223), a radioisotope emitting genotoxic ...
The overarching goal of this thesis is to establish a well-characterized platform to investigate the...
The bone-seeking radiopharmaceutical Xofigo (Radium-223 dichloride) has demonstrated both extended s...
BACKGROUND: Radium-223 dichloride (radium-223), an alpha emitter, selectively targets bone metastas...
Michael R Harrison, Terence Z Wong, Andrew J Armstrong, Daniel J GeorgeDuke Cancer Institute, Durham...
The use of α-particle radionuclide emitters in the treatment of bone metastasis has been an active a...
BackgroundRadium-223 is a targeted alpha-particle therapy that improves survival in men with metasta...
Various single or multi-modality therapeutic options are available to treat pain of bone metastasis ...
IMPORTANCE Targeted alpha therapy attempts to deliver systemic radiation selectively to cancer cells...
Importance Targeted alpha therapy attempts to deliver systemic radiation selectively to cancer cells...
Radium-223 dichloride (223Ra) is the first, recently approved, α-particle-emitting radiopharmaceutic...
Review[Abstract] Radionuclides have been widely used for cancer treatment. Recently, new research ab...
Important consideration in development of effective radiotherapy is the nature of the radiation emit...
Bone-metastatic, castration-resistant prostate cancer (bmCRPC) represents a lethal stage of the most...
Painful bone metastases are common in prostate cancer, with current treatments including non-steroid...